News

September 26, 2017September 26, 2017

FDA Grants Accelerated Approval to Keytruda for Gastric Cancer

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Merck’s Keytruda (pembrolizumab) for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The ... Read more

September 26, 2017

FDA OKs Opdivo as Liver Cancer Therapy for Patients Who Did Not Respond to Nexavar

News

Patients with the most common liver cancer subtype, hepatocellular carcinoma (HCC), who have not responded to Nexavar (sorafenib), now can be treated with Opdivo (nivolumab), following an accelerated approval granted by ... Read more

September 25, 2017September 25, 2017

UK’s NICE Approves Opdivo as Second-line NSCLC Treatment through Cancer Drugs Fund

News

Non-small cell lung cancer patients in England and Wales who failed prior chemotherapy can now access Opdivo (nivolumab) as a second-line treatment, following the therapy’s recent approval by the ... Read more

September 22, 2017September 22, 2017

European Commission Approves Bavencio as First Immunotherapy for Adult Metastatic Merkel Cell Carcinoma

News

The European Commission (EC) has granted Bavencio (avelumab) marketing approval as the first immunotherapy to treat the aggressive skin cancer metastatic Merkel cell carcinoma in adults. The decision will allow ... Read more

September 21, 2017September 21, 2017

Opdivo, HPV Cancer Vaccine Combo Improves Response Rates in Oropharyngeal Cancer Patients

News

A Phase 2 clinical trial found that the combination of Opdivo (nivolumab) and a cancer vaccine increased response rates in patients with throat tumors (oropharyngeal tumors) caused by the ... Read more

September 20, 2017

Tafinlar-Mekinist Combo is Highly Effective Adjuvant Therapy for Melanoma, Researchers Say

News

A combination of Tafinlar (dabrafenib) and Mekinist (trametinib) nearly halved the risk of relapse or death among patients with advanced melanoma with high-risk mutations, according to trial results presented ... Read more

September 19, 2017September 19, 2017

Keytruda Better than Standard Treatment for Advanced Head and Neck Cancer, Keynote-040 Study Shows

News

Keytruda (pembrolizumab) may be more beneficial than standard therapy for patients whose head and neck cancer has spread or returned after a first round of chemotherapy. That’s the conclusion of a Phase ... Read more

September 18, 2017

X4P-001 and Inlyta Combo Shows Promise Against Kidney Cancer, Trial Indicates

News

A combination of X4P-001 and Inlyta (axitinib) has shown signs of activity against clear cell renal cell carcinoma (ccRCC) in a Phase 1/2 clinical trial. X4 Pharmaceuticals, which developed X4P-001, presented the findings in a poster session at ... Read more

September 15, 2017September 15, 2017

Imfinzi Reduces Risk of Disease Progression in Advanced NSCLC Patients, PACIFIC Trial Shows

News

Imfinzi (durvalumab) increased the time to disease progression or death in patients with advanced, non-small cell lung cancer (NSCLC) who had not progressed following standard care with platinum-based concurrent ... Read more

September 15, 2017September 15, 2017

Updated Phase 3 Trial Results Continue to Favor Keytruda as Second-Line Treatment for Bladder Cancer

News

Patients with advanced urothelial cancer who received one prior line of chemotherapy live significantly longer when given Keytruda (pembrolizumab) as a second-line treatment instead of the standard of care ... Read more